The limited number of validated molecular subtypes and the coexistence of tumor cells with both molecular signatures in the same patients are likely a consequence that most PDACs are driven by few somatic mutations that occur at high frequency (i.e., KRAS, CDKN2A, TP53, and SMAD4). Here, CDKN2A is linked to neoplasm.